Delix Therapeutics

Executive Summary

Delix Therapeutics is a preclinical-stage biotech company pioneering neuroplastogens—a novel class of small molecules that promote rapid and sustained neuroplasticity. Founded in 2019 and based in Boston, the company aims to address the significant unmet need in neuropsychiatric disorders such as depression, PTSD, and substance use disorders. Unlike traditional psychedelics, Delix’s compounds are designed to be non-hallucinogenic, potentially enabling scalable office-based treatment without the need for supervised psychedelic sessions. The company’s platform leverages structure-based drug design to create compounds that robustly enhance dendritic spine growth and synaptic connectivity, thereby reversing the neuronal atrophy associated with chronic stress and psychiatric conditions. Delix has advanced its lead program, DLX-001, through preclinical studies demonstrating safety and efficacy in animal models, and is preparing for clinical development. The company has attracted significant investor interest and has a strong intellectual property portfolio. If successful, Delix’s neuroplastogens could revolutionize the treatment of brain health disorders by providing fast-acting, durable, and accessible therapies. Looking ahead, Delix is approaching key value-creating milestones. The company is expected to file an Investigational New Drug (IND) application with the FDA in the near term, likely in the second half of 2026, to initiate first-in-human studies for DLX-001. Additionally, Delix may announce a strategic partnership or secure Series B financing to fund its clinical pipeline. The company’s progress is closely watched by investors and the biotech community, as neuroplastogens represent a paradigm shift in psychiatric medicine. While preclinical stage carries risk, the robust scientific rationale and early data provide a compelling thesis. Delix’s ability to execute on its clinical plans and demonstrate safety and efficacy in humans will be critical for future value appreciation.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for DLX-00180% success
• Q4 2026Series B Financing or Strategic Partnership70% success
• Q1 2027Initiation of Phase 1 Clinical Trial for DLX-00175% success